The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
Written by : Susan M. Janicki, Ph.D. & Agnes Juang, Ph.D. The Federal Trade Commission (FTC) issued a policy statement [1] on September 14, 2023, stating that “[b]rand drug manufacturers may be harming generic competition through the improper listing…
December 5, 2023Pharma & ANDA4 min read